+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Physical activity measured with implanted devices predicts patient outcome in chronic heart failure

Physical activity measured with implanted devices predicts patient outcome in chronic heart failure

Circulation. Heart Failure 7(2): 279-287

Physical activity (PA) predicts cardiovascular mortality in the population at large. Less is known about its prognostic value in patients with chronic heart failure (HF). Data from 836 patients with implantable cardioverter defibrillator without or with cardiac resynchronization therapy enrolled in the Sensitivity of the InSync Sentry OptiVol feature for the prediction of Heart Failure (SENSE-HF)(1) study and the Diagnostic Outcome Trial in Heart Failure (DOT-HF) were pooled. The devices continuously measured and stored total daily active time (single-axis accelerometer). Early PA (average daily activity over the earliest 30-day study period) was studied as a predictor of time to death or HF-related hospital admission (primary end point). Data from 781 patients were analyzed (65±10 years; 85% men; left ventricular ejection fraction, 26±7%). Older age, shorter height, ischemic cause, peripheral artery disease, atrial fibrillation, diabetes mellitus, rales, peripheral edema, higher New York Heart Association class, lower diastolic blood pressure, and no angiotensin II receptor blocker/angiotensin-converting enzyme inhibitor use were associated with reduced early PA. The primary end point occurred in 135 patients (15±7 months of follow-up). In multivariable analysis including baseline variables, early PA predicted death or HF hospitalization, with a 4% reduction in risk for each 10 minutes per day additional activity (hazard ratio [HR], 0.96; confidence interval [CI], 0.94-0.98; P=0.0002 compared with a model with the same baseline variables but without PA). PA also predicted death (HR, 0.93; CI, 0.90-0.96; P<0.0001) and HF hospitalization (HR, 0.97; CI, 0.95-0.99; P=0.011). Early PA, averaged over a 30-day window early after defibrillator implantation or cardiac resynchronization therapy in patients with chronic HF, predicted death or HF hospitalization, as well as mortality and HF hospitalization separately, accounting for baseline HF severity. Clinical Trial Registration Information- URL: Unique identifiers: NCT00400985, NCT00480077.

(PDF emailed within 0-6 h: $19.90)

Accession: 054993388

Download citation: RISBibTeXText

PMID: 24519908

DOI: 10.1161/CIRCHEARTFAILURE.113.000883

Related references

Physical Activity Measured by Implanted Devices Predicts Atrial Arrhythmias and Patient Outcome: Results of IMPLANTED (Italian Multicentre Observational Registry on Patients With Implantable Devices Remotely Monitored). Journal of the American Heart Association 7(5): -, 2018

Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). Journal of Cardiac Failure 16(12): 964-970, 2011

A Multisensor Algorithm Predicts Heart Failure Events in Patients With Implanted Devices: Results From the MultiSENSE Study. Jacc. Heart Failure 5(3): 216-225, 2018

Monitoring of physical activity and heart rate variability in patients with chronic heart failure using cardiac resynchronization devices. American Journal of Cardiology 95(9): 1104-1107, 2005

Heart rate variability monitored by the implanted device predicts response to CRT and long-term clinical outcome in patients with advanced heart failure. European Journal of Heart Failure 10(11): 1073-1079, 2008

Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. Kidney International 93(4): 952-960, 2017

Device-measured physical activity versus six-minute walk test as a predictor of reverse remodeling and outcome after cardiac resynchronization therapy for heart failure. American Journal of Cardiology 113(9): 1523-1528, 2014

Biomarkers of inflammation in patients with chronic heart failure and implanted devices for cardiac resynchronization therapy. Kardiologiia 52(8): 38-43, 2012

γ-Glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure. Journal of Cardiac Failure 17(7): 577-584, 2012

Augmented peripheral chemosensitivity better than depressed heart rate variability and baroreflex sensitivity predicts poor outcome in patients with chronic heart failure. Circulation 98(17 SUPPL ): I210-I211, Oct 27, 1998

Gamma-Glutamyltransferase Rather Than Total Bilirubin Predicts Outcome in Chronic Heart Failure. Journal of Cardiac Failure 17(7): 0-584, 2011

Flow-mediated vasodilatation predicts outcome in patients with chronic heart failure. Journal of the American College of Cardiology 43(5 Supplement A): 198A, March 3, 2004

Flow-Mediated Dilation Normalization Predicts Outcome in Chronic Heart Failure Patients. Journal of Cardiac Failure 19(4): 260-267, 2013

Flow-mediated dilation normalization predicts outcome in chronic heart failure patients. Journal of Cardiac Failure 19(4): 260-267, 2014

Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. International Journal of Cardiology 115(2): 151-155, 2006